A diagnostics technology platform for immuno-oncology
About Asylia Diagnostics
We empower cancer patients, medical oncologists, and drug development companies to have an informed decision about the safety of immunotherapy by providing reliable companion diagnostics technology platform. Our first product - already in clinical studies in Belgium - is targeting hyperprogressive disease, a severe adverse effect of immune checkpoint blockade affecting 5-29% of patients.
Our involvement
Asylia Diagnostics joined imec.istart in 2019





.png)






